Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference
22. September 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging
20. September 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms...
Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
10. August 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
09. August 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. Second quarter CAPLYTA...
Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast
02. August 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
07. Juni 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg Mean change from baseline in...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
26. Mai 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
10. Mai 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
05. Mai 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast
04. Mai 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...